Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Official Title: “Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)”

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Inclusion Criteria:

• High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
• Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

• Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
• Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: AstraZeneca Industry

Overall Clinical Trial Officials and Contacts

Ingrid van Geel, MD Study Chair AstraZeneca  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00396110

Study ID Number: 25V06

ClinicalTrials.gov Identifier: NCT00396110

Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)